Plain-English translation of NCT03937635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Smoldering myeloma is an early form of blood cancer that may progress to active myeloma. This trial tests whether adding to two standard myeloma medications ( and ) can help people with high-risk smoldering myeloma live longer and delay progression. The study will compare people who receive the medication against those who receive the two standard drugs alone.
People with high-risk smoldering myeloma are at serious risk of developing active myeloma within a few years. Doctors want to know whether starting treatment early with this medication can help prevent that progression and improve survival compared to waiting or using standard treatment alone.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication plus two standard drugs or just the two standard drugs. If you receive , you'll get infusions by vein on specific days (weekly for the first two months, then less frequently). You'll take by mouth daily and on certain days of each 28-day cycle. Treatment continues for up to 24 cycles (about 2 years) unless your disease worsens or side effects become too severe. You'll have frequent blood tests and clinic visits to monitor your health and answer questions about how you're feeling.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States